Dasatinib is a safe therapy for imatinib-resistant patients with chronic-phase CML

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷 / 9期
关键词：
D O I：
10.1038/ncponc0891
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：503 / 503
相关论文
共 50 条
  • [41] BENEFITS/RISKS OF DASATINIB THERAPY IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA: PHYSICIAN'S AND PATIENT'S
    Ionova, T.
    Nikitina, T.
    Gritsenko, T.
    Ivanova, V.
    Kuchma, G.
    Shnaider, T.
    Sannikova, I.
    Fedorenko, D.
    Kurbatova, K.
    HAEMATOLOGICA, 2013, 98 : 559 - 559
  • [42] Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
    Guilhot, Francois
    Apperley, Jane
    Kim, Dong-Wook
    Bullorsky, Eduardo O.
    Baccarani, Michele
    Roboz, Gail J.
    Amadori, Sergio
    de Souza, Carmino A.
    Lipton, Jeffrey H.
    Hochhaus, Andreas
    Heim, Dominik
    Larson, Richard A.
    Branford, Susan
    Muller, Martin C.
    Agarwal, Prasheen
    Gollerkeri, Ashwin
    Talpaz, Moshe
    BLOOD, 2007, 109 (10) : 4143 - 4150
  • [43] Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
    Cortes, Jorge E.
    Jones, Dan
    O'Brien, Susan
    Jabbour, Elias
    Ravandi, Farhad
    Koller, Charles
    Borthakur, Gautam
    Walker, Brenda
    Zhao, Weiqiang
    Shan, Jianqin
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 398 - 404
  • [44] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [45] COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL
    Asano, E.
    Nita, M.
    Moellmann-Coelho, A.
    Rached, R.
    Donato, B.
    Rahal, E.
    VALUE IN HEALTH, 2009, 12 (07) : A280 - A281
  • [46] Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic
    Klamova, H.
    Faber, E.
    Zackova, D.
    Markova, M.
    Voglova, J.
    Cmunt, E.
    Novakova, L.
    Machova-Polakova, K.
    Moravcova, J.
    Dvorakova, D.
    Michalova, K.
    Brezinova, J.
    Oltova, A.
    Jarosova, M.
    Cetkovsky, P.
    Indrak, K.
    Mayer, J.
    NEOPLASMA, 2010, 57 (04) : 355 - 359
  • [47] Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results
    Shah, Neil P.
    Rousselot, Philippe
    Schiffer, Charles A.
    Rea, Delphine
    Cortes, Jorge E.
    Milone, Jorge
    Mohamed, Hesham
    Healey, Diane
    Kantarjian, Hagop
    Hochhaus, Andreas
    Saglio, Giuseppe
    BLOOD, 2014, 124 (21)
  • [48] DASATINIB COMPARED TO IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP): RESULTS FROM THE RANDOMIZED PHASE 3 DASISION TRIA
    Baccarani, M.
    Shah, N.
    Kantarjian, H.
    Cortes, J.
    Shah, S.
    Ayala, M.
    Moiraghi, B.
    Mayer, J.
    Bradley-Garelik, M.
    Zhu, C.
    Hochhaus, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 231 - 231
  • [49] THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO
    Juarez-Garcia, A.
    Uc-Coyoc, R.
    Hernandez-Rivera, G.
    Rangel, S.
    Taylor, M. J.
    Litalien, G.
    Donato, B.
    VALUE IN HEALTH, 2009, 12 (07) : A495 - A495
  • [50] Grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CML-CP) patients treated with nilotiniband dasatinib
    Stephens, J.
    Carpiuc, K. T.
    Snedecor, S. J.
    Botteman, M. F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 205 - 206
12345